Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
RESEARCH TOOLSreports
Holding GPCR?
Track your performance easily
GPCR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$26.61 - $66.38
Previous Close$34.17
Volume1.08M
Average Volume (3M)684.05K
Market Cap
$1.96B
Enterprise Value$1.03B
Total Cash (Recent Filing)$927.12M
Total Debt (Recent Filing)$4.67M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Mar 27, 2025EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding57,260,673
10 Day Avg. Volume716,171
30 Day Avg. Volume684,049
Standard Deviation0.26
R-Squared0.21
Alpha0.11
Financial Highlights & Ratios
Price to Book (P/B)2.18
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-27.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-9.03
Forecast
1Y Price Target
$89.14Price Target Upside160.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Structure Therapeutics, Inc. Sponsored ADR News
PremiumCompany Announcements
Structure Therapeutics Reports Strong Q3 2024 Results
PremiumPre-Earnings
Is GPCR a Buy, Before Earnings?
PremiumCompany Announcements
Structure Therapeutics Announces Key Executive Leadership Changes
Bulls Say, Bears Say
Bulls Say
Innovative Drug DevelopmentGSBR-1290 is poised to become the second oral GLP-1R agonist on the market, and the comprehensive design of these Phase 2b studies is intended to establish a differentiated profile for the drug by providing a comprehensive data set.
Leadership In Metabolic TherapiesStructure's rapid progress solidifying itself as a leader in the metabolic space.
Market Expansion PotentialSmall molecules could bring GLP1+ therapy to underserved populations globally, with less plastic and simpler supply chains.
Bears Say
Health RisksIncreased heart rate is a common side effect of treatment, which could be concerning for patients with cardiovascular conditions.
Market SentimentShort interest is notably high, indicating that a significant portion of investors are betting against the stock.
Product ConcernsA high percentage of patients using the product experience adverse effects like nausea, vomiting, and constipation, raising concerns about its safety and tolerability.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $26.61 and its highest was $66.38 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Currently, no data Available
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Mar 27, 2025 which is in 130 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Nov 13, 2024. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.182 by -$0.018.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -$0.23.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 57,260,674 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.182. Following the earnings report the stock price went up 3.629%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Among the largest hedge funds holding Structure Therapeutics, Inc. Sponsored ADR’s share is Driehaus Capital Management LLC. It holds Structure Therapeutics, Inc. Sponsored ADR’s shares valued at 101M.
---
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.14 (160.87% Upside)
$89.14 (160.87% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 554.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.28%
12-Months-Change
Fundamentals
Return on Equity
-20.36%
Trailing 12-Months
Asset Growth
331.31%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc is a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical need.
---
GPCR Stock 12 Month Forecast
Average Price Target
$89.14
▲(160.87% Upside)
Technical Analysis
Best Analysts Covering GPCR
1 Year
1 Year Success Rate
9/13 ratings generated profit
1 Year Average Return
+17.92%
reiterated a buy rating 3 months ago
Copying David Risinger's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +17.92% per trade.
---